АНТИГИПЕРТЕНЗИВНАЯ ЭФФЕКТИВНОСТЬ И ВЛИЯНИЕ НА СОСТОЯНИЕ ОРГАНОВ-МИШЕНЕЙ ТЕРАПИИ ЗОФЕНОПРИЛОМ, В ТОМ ЧИСЛЕ В СОЧЕТАНИИ С НЕБИВО ЛО ЛОМ

1. Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Российские рекомендации (второй пересмотр). Комитет экспертов Всероссийского научного общества кардиологов. Секция артериальной гипертонии ВНОК. Москва 2004 г. Приложение к журналу "Кардиоваскулярная терапия и профилактика".

2. Титов В.Н., Тарасов А.В. Микроальбуминурия: патофизиология, диагностическое значение и методы исследования//Тер. арх. 1988; 134-140.

3. Mogensen С.Е., Keane W.F., Bennett I.H. et al. Prevention of diabetic renal disease with special reference to microalbuminuria//Lancet 1995; 346: 1080-1084.

4. Schlessinger S.D., Tankersey M.R., Crtis J.J. Clinical documentation or end-stage renal disease due to hypertension//Am J Kidney Dis 1994; 23: 655-660.

5. Staessen J., Fagard R., Lijnen P. et al. The hypotensive effect of propranolol in captopril-treated patients does not involve the plasma renin-angiotensin-aldosterone system//Clin Sci 1981; 61: 441-444.

6. Pickering T.G., Case D.B., Sullivan P.A., Laragh J.H. Comparison of antihypertensive and hormonal effects of captopril and propranolol at rest and during exercise//Am J Cardiol 1982; 49: 1566-1568.

7. Sullivan P.A., Daly B., O'Connor R. Enalapril versus combined enalapril and nadolol treatment: effects on blood pressure, heart rate, humoral variables, and plasma potassium at rest and during exercise in hypertensive patients//Cardiovasc Drugs Ther 1992; 6: 261-265.

8. Ратова Л.Г., Дмитриев В.В., Толпыгина С.Н., Чазова И.Е. Суточное мониторирование артериального давления в клинической практике. Консилиум. Приложение "Артериальная гипертензия" 2001: 3-14.

9. Рогоза А.Н., Никольский В.П., Ощепкова Е.В. и др. Суточное мониторирование артериального давления (Методические вопросы)/Под ред. Г.Г. Арабидзе и О.Ю. Атькова. М., 1997.

10. The EuroQol Group. EuroQol: a new facility for the measurement of health related quality of life//Health Policy 1990; 16: 199-208.

11. Brenner B., Hemodynamicalry mediated glomerular injury and the progressive nature of kidney disease//Kidney Int. 1983; 23: 647-655.

12. Тиц Н.У. Клиническая оценка лабораторных тестов: пер. с англ. М.: Медицина, 1986.

13. Sommers S.C., Melamed J. Renal pathology of essential hypertension//Am J Hypertens. 1990; 3(7): 583-587.

14. Lozance L., Zafirovska K., Bogdanovska S. Renal dysfunction and early differences in 24-hour ABPM in subjects predisposed for essential hypertension//Srp Arh Celok Lek 1996; 124: 197-199.

15. Cerasola G., Cottone S., Mule G. et al. Microalbuminuria, renal dysfunction a. nd cardiovascular complication in essential hypertension//J of hypertension 1996; 14: 915-920.

16. Redon J., Miralles A., Pascual J.M. et al. Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension//J Hypertens 1997; 15: 79-86.

17. Toto R., Shultz P., Raij L. Eficacy and tolerability of losartan in hypertensive patients with renal impairment//Hypertension 1998; 31; 684-691.

18. Nielsen S., Dollerup J., Nielsen В. et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 mounths study//Nephrol Dial Transplant 1997; 12: 19-22.

19. Franz I.W., Behr U., Ketelhut R. Resting and exercise blood pressure with atenolol, enalapril and a low-dose combination//J Hypertens 1987; 5(Supp 3): 37-41.

20. Soininen K., Gerlin-Piira L., Suihkonen J. et al. A study of the effects of lisinopril when used in addition to atenolol//J Hum Hypertens 1992; 6: 321-324.

21. Bursztyn M., Gavras I., Gourley L. et al. Effect of combination therapy with atenolol and the angiotensin-converting enzyme inhibitor benazepril//Clin Ther 1994; 16: 429-436.

22. Huttunen M., Lampainen E., Lilja M. et al. Which anti-hypertensive to add to a beta-blocker: ACE inhibitor or diuretic?//J Hum Hypertens 1992; 6: 121-125.

23. MacConnachie A.M., Maclean D. Low dose combination. Antihypertensive therapy: additional efficacy without additional adverse effects?//Drug Safety 1995; 12: 85-90.

24. Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease//Lancet 1990; 335: 827-838.

25. MacGregor G.A., Markandu N.D., Smith S.J. et al. Captopril: contrasting effects of adding hydrochlorothiazide, propranolol, or nifedipine//J Cardiovasc Pharmacol 1985; 7: 82-87.

26. Ferguson R. K., Vlasses P.H., Koffer H. et al. Effect of captopril and propranolol, alone and in combination, on the response to isometric and dynamic exercise in normotensive and hypertensive men.// Pharmacotherapy 1983; 3: 125-130.

27. Giatras I., Lau J., Levey A.S. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials//Ann Intern Med 1997; 127: 337-345.

28. Wood W.G., Elias M.F., Schultz N.R. Anxiety and depression in young and middle aged hypertensive and normotensive subjects//Exp Aging Res 1979; 1(15): 15-30.

29. Battersby C., Hartley K., Fletcher A.F. Quality of life in treated hypertension: a case-control community based study//J Hum Hypertens 1995; 12 (19): 981-986.

30. Klocek M., Kawecka-Jaszcz K. Quality of life in patients with essential arterial hypertension. Lhe effect of socio-demographic and clinical factors//Przegl Lek 2003; 60 (2): 92-100.